New Dual-Action antibody could extend lives in stomach cancer
NCT ID NCT07700979
First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time
Summary
This phase 3 trial tests whether adding an experimental drug called cadonilimab to standard chemotherapy helps people with advanced stomach or gastroesophageal junction cancer live longer. Cadonilimab is a bispecific antibody that targets two immune checkpoints (PD-1 and CTLA-4) to boost the body's cancer-fighting response. The study compares this new combination against chemotherapy alone or with nivolumab, another immunotherapy. Participants have HER2-negative, previously untreated, unresectable or metastatic disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a bispecific antibody called cadonilimab that targets PD-1 and CTLA-4, combined with chemotherapy
- What this could lead to
- If successful, this could offer a new first-line treatment option for people with advanced gastric cancer, potentially improving survival.
- What could go wrong
- This is an early-stage trial, and the experimental drug may not prove more effective than existing treatments. Side effects from the combination therapy could be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Baylor Scott & White Health
Dallas, Texas, 75246, United States
-
Beijing Friendship Hospital, Capital Medical University
Beijing, China
Contact
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Guangdong Provincial People's Hospital
Guangzhou, China
Contact
-
Henry Ford Health
Detroit, Michigan, 48202, United States
Contact
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Contact
-
Mayo Clinic
Phoenix, Arizona, 85054, United States
Contact
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Mount Sinai
New York, New York, 10029, United States
Contact
-
Narodowy Instytut Onkologii-im. Marii Sklodowskiej Curie Panstwowy Instytut Badawczy - w Warszawie
Warsaw, Poland
Contact
-
Oregon Health and Science University
Portland, Oregon, 97239, United States
Contact
-
Peking University Cancer Hospital, Gastrointestinal Cancer Center I
Beijing, China
Contact
-
Peking University Cancer Hospital, Gastrointestinal Oncology
Beijing, China
Contact
-
Pratia MCM Kraków
Krakow, Poland
-
Pratia Poznań
Poznan, Poland
Contact
-
Rocky Mountain Cancer Centers
Denver, Colorado, 80218, United States
Contact
-
Sarah Cannon Research Institute (SCRI) - Oncology Partners
Nashville, Tennessee, 37203, United States
Contact
-
UCLA Health
Los Angeles, California, 90095, United States
Contact
-
Univerity Marburg
Marburg, Germany
-
Universitaetsklinikum Essen
Essen, North Rhine-Westphalia, Germany
Contact
-
University Cancer Center Frankfurt
Frankfurt, Germany
Contact
-
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, 53792, United States
Contact
-
Universitätsmedizin der Johannes Gutenberg-Universität
Mainz, Germany
Contact
-
Yale School of Medicine
New Haven, Connecticut, 06510, United States
Contact
-
Zhongshan Hospital Fudan University
Shanghai, China
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Triple-Drug attack slow down stomach cancer?
- Can a Three-Drug cocktail shrink stomach tumors before surgery?
- Can a less extensive stomach surgery preserve appetite better?
- New drug combo aims to outperform immunotherapy in Hard-to-Treat stomach cancer
- Breath of life: new test could sniff out gut cancers before they spread
- Drug cocktail aims to shrink Hard-to-Treat stomach cancers